Susquehanna International Group, LLP Cyclacel Pharmaceuticals, Inc. Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$0.52 - $0.76 $6,402 - $9,357	12,312 New	12,312 $7,000
Q2 2022 Aug 15, 2022	BUY	$6.1 - $7.15 $61,036 - $71,542	10,006 Added 46.51%	31,519 $34,000
Q1 2022 May 16, 2022	BUY	$5.93 - $7.6 $20,114 - $25,779	3,392 Added 18.72%	21,513 $66,000
Q4 2021 Feb 14, 2022	BUY	$6.04 - $8.03 $28,877 - $38,391	4,781 Added 35.84%	18,121 $70,000
Q3 2021 Nov 15, 2021	BUY	$8.02 - $11.0 $106,986 - $146,740	13,340 New	13,340 $70,000
Q2 2021 Aug 11, 2021	SELL	$7.59 - $10.48 $103,983 - $143,576	-13,700 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$6.86 - $9.24 $93,982 - $126,588	13,700 New	13,700 $97,000

Ticker CYCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,539,200
Market Cap $12.5M
Description
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.